[Linezolide in paediatrics].
The spread of multiresistant Gram positive bacteria required the development of new drugs. Linezolid, a new oxazolidinone, is active against these pathogens and is marketed for the treatment of severe glycopeptides-resistant Gram positive-bacteria in adults. Moreover, the availability of intravenous and oral formulation with an excellent bioavailability of the latter, is hoped to facilitate the management of these infections. Most information regarding the pharmacoketic profile, efficacy and tolerability of linezolid in pediatric derived from adults studies. In this review we summarize evidence regarding the uses of linezolid in children focusing on the clinical efficacy data and safety in serious Gram-positive infections and also in compassional uses.
Moulin
F
F
Urgences Pédiatriques, Hôpital saint Vincent de Paul, 82, Avenue Denfert Rochereau, 75014 Paris, France. florence.moulin@svp.aphp.fr
Ménager
C
C
D000081:Acetamides / Q000008:administration & dosage / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D006094:Gram-Positive Bacteria / Q000187:drug effects; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000635:transmission; D006801:Humans; D007275:Injections, Intravenous; D000069349:Linezolid; D023303:Oxazolidinones / Q000008:administration & dosage / Q000627:therapeutic use*
D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D000069349:Linezolid